STOCKHOLM, SE / ACCESSWIRE / June 21, 2022 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical agency that develops a broad portfolio of drug candidates for illnesss have an effect oning the central nervous system, with tasks in each Alzheimer’s illness and ache, right now introduced that The primary affected person has been included in a Half II medical trial with ACD440, the main non-opioid drug candidate Inside the Painless platform which is being developed for peripheral neuropathic ache.
This follows the current approvals from regulatory authorities to begInside the research. The Half II medical trial is a double-blind, placebo-managed, randomized cross-over research evaluating the efficacy, safety, and pharmacokinetics of AlzeCure’s main drug candidate in ache, ACD440. Outcomes from the research are anticipated in mid-2023.
ACD440 is a TRPV1 antagonist and first-in-class native remedy for affected individuals with peripheral neuropathic ache. The invention of TRPV1, which is The idea for the enterprise, was awarded the Nobel Prize in Physiology or Medicine in 2021. ACD440, which is utilized as a gel, is The agency’s main drug candidate Inside the Painless platform and carried out a constructive phase Ib research in 2021.
The medical want in neuropathic ache Might be very good, not least To Search out options to opioids. The market for neuropathic ache is The solely largest market phase in ache remedy, with annual gross sales of over USD 11 billion. As a lot as 80% …….
